Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 19/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.57 |
| ▸ | RPTOR | Q8N122 | 9/20 | 0.44 |
| ▸ | MLST8 | Q9BVC4 | 9/20 | 0.44 |
| ▸ | RICTOR | Q6R327 | 2/20 | 0.42 |
| ▸ | MAPKAP1 | Q9BPZ7 | 2/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30365739 | 0.79 | MTOR (0.49) | MTORPIK3CARPTORMLST8CSF1R | |
| SCHEMBL29522044 | 0.79 | MTOR (0.65) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL138077 | 0.79 | MTOR (0.65) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL481757 | 0.73 | MTOR (0.61) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL136021 | 0.73 | MTOR (1.00) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL29523011 | 0.73 | MTOR (1.00) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL3381901 | 0.71 | CD274 (0.33) | — | |
| SCHEMBL152826 | 0.70 | MTOR (0.56) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL157126 | 0.70 | MTOR (0.56) | MTORPIK3CARPTORMLST8RICTOR | |
| SCHEMBL138532 | 0.70 | MTOR (0.56) | MTORPIK3CARPTORMLST8RICTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3660020-B1 | PROCESS FOR THE SYNTHESIS OF MTOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230119470-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARM LLC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11292796-B2 | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2022-04-05 | — | — | US | disclosed |
| US-20200262840-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARM LLC (US) | 2020-08-20 | — | — | US | disclosed |
| US-10683298-B2 | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2020-06-16 | — | — | US | disclosed |
| EP-3660020-A1 | PROCESS FOR THE SYNTHESIS OF MTOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3103803-B1 | INTERMEDIATES FOR THE SYNTHESIS OF MTOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2020-03-11 | — | — | EP | disclosed |
| EP-3091021-B1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARM LLC (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20190077806-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARM LLC (US) | 2019-03-14 | — | — | US | disclosed |
| US-10167290-B2 | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2019-01-01 | — | — | US | disclosed |
| US-20130245254-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-8507492-B2 | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-08-13 | — | — | US | disclosed |
| US-8492381-B2 | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2493472-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | Signal Pharmaceuticals, LLC (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120071658-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITOR FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | PERRIN-NINKOVIC SOPHIE (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120059164-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITOR FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | PERRIN-NINKOVIC SOPHIE (US) | 2012-03-08 | — | — | US | disclosed |
| US-8110578-B2 | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-02-07 | — | — | US | disclosed |
| US-20110137028-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-06-09 | — | — | US | disclosed |
| WO-2011053518-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-05-05 | — | — | WO | disclosed |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167290-B2 | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors | MTOR, RICTOR, RPS6KA2 | MTOR 1/4885PIK3CA 63/4885RPTOR 30/4885 |
| US-10683298-B2 | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors | MTOR, RICTOR, PDK1 | MTOR 1/4885PIK3CA 73/4885RPTOR 5/4885 |
| US-20230119470-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885PIK3CA 6/4885RPTOR 3/4885 |
| US-11292796-B2 | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885PIK3CA 80/4885RPTOR 3/4885 |
| US-20120071658-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITOR FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885PIK3CA 6/4885RPTOR 3/4885 |
| US-20200262840-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885PIK3CA 6/4885RPTOR 3/4885 |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885PIK3CA 10/4885RPTOR 3/4885 |
| US-20110137028-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | AGER, GPR119, REL | MTOR 595/4885PIK3CA 2787/4885RPTOR 478/4885 |
| US-20130245254-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | AGER, GPR119, REL | MTOR 595/4885PIK3CA 2787/4885RPTOR 478/4885 |
| US-20120059164-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITOR FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885PIK3CA 6/4885RPTOR 3/4885 |
| US-20190077806-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885PIK3CA 6/4885RPTOR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.